StockpollyBeta
Get App
Popularity #2,663
BCAX · NASDAQ · Biotechnology

Bicara Therapeutics (BCAX)

Developing a bifunctional antibody program for head and neck and other solid tumors.

$21.41
vs last close−1.37 (−6.01%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
101415202127423241416060
Research & development7111216162034256334846
33345777881314
General & administrative33345777881314
Other expenses0000000027000
Operating income−10−14−15−20−21−27−42−32−41−41−60−60
−1313336554445
Interest income013336554445
Other non-operating income1312−3−3−3−6−5−5−4−4−4−5
Income before tax−23−12−13−17−17−21−37−27−36−37−56−55
Income tax expense000000000000
Net income from continuing operations−23−12−13−17−17−21−37−27−36−37−56−55
Other adjustments000000000000
Net income−23−12−13−17−17−21−37−27−36−37−56−55
EPS, basic−$0.42−$0.23−$0.27−$0.27−$0.32−$0.38−$0.68−$0.50−$0.67−$0.68−$0.93−$0.82
EPS, diluted−$0.42−$0.23−$0.27−$0.27−$0.32−$0.38−$0.68−$0.50−$0.67−$0.68−$0.93−$0.82
Weighted average shares, basic545354545454545555556168
Weighted average shares, diluted545354545454545555556168
EBITDA−23−26−12−17−17−21−37−27−36−37−56−55
Depreciation & amortization000000000001
EBIT−23−26−13−17−17−21−37−27−36−37−56−55